2026 ISPE Europe Annual Conference Session: A CQV Early Engagement Checklist: BOD Thru DD

ISPE (International Society for Pharmaceutical Engineering)
ISPE (International Society for Pharmaceutical Engineering)Mar 30, 2026

Why It Matters

Implementing early CQV transforms validation from a reactive hurdle into a proactive risk‑control strategy, saving time and protecting GMP compliance.

Key Takeaways

  • Early CQV engagement prevents rework during commissioning phase.
  • Five‑phase CQV model starts at basis of design.
  • Toolkit provides forms, AI prompts, templates, risk tools.
  • Leadership role of CQ reduces GMP compliance risk.
  • Early CQV is risk control, not additional workload.

Summary

The video outlines an early‑engagement checklist for Commissioning, Qualification and Validation (CQV) that begins at the Basis of Design (BOD) and continues through due‑diligence activities.

It explains why most issues surface during the CNQ phase—earlier decisions funnel problems downstream—and introduces a five‑phase CQV model that project managers can deploy as soon as the BOD is approved. The presenter also unveils an early‑CQV toolkit containing standardized forms, AI prompt sets, plan templates and risk‑assessment tools.

A key quote emphasizes the mindset shift: “Early CQV is not extra work. It’s risk control for the whole job.” The speaker cites a real‑world implementation that streamlined hand‑offs and eliminated rework in a recent pharmaceutical facility.

For manufacturers, adopting this approach promises reduced rework, shorter timelines, and stronger GMP compliance, turning CQV from a downstream bottleneck into a proactive risk‑management function.

Original Description

Comments

Want to join the conversation?

Loading comments...